Advertisement

Hormones

pp 1–8 | Cite as

Increased circulating levels of irisin are associated with cardiovascular risk factors in subjects with acromegaly

  • Mehmet CalanEmail author
  • Mustafa Demirpence
Original Article

Abstract

Aims

Irisin, a peptide secreted from muscle and adipose tissues, is associated with insulin resistance as well as metabolic and cardiovascular diseases. Acromegaly is a rare disorder caused by overproduction of growth hormone (GH) and is associated with functional and structural differentiation of adipose and muscle tissues. Acromegalic subjects are also at risk of vascular diseases and metabolic dysfunctions. We aimed to determine the altered levels of irisin in subjects with active acromegaly and controlled acromegaly and in controls, and to ascertain whether there is an association between irisin and hormonal and cardiometabolic parameters.

Methods

We enrolled 40 subjects with active acromegaly, 30 subjects with controlled acromegaly, and 40 control subjects of matched age, gender, BMI, and occurrence of hypertension, diabetes, and metabolic syndrome distribution in the present cross-sectional study. Hormonal and metabolic parameters, carotid intima media thickness (cIMT), and epicardial fat thickness (EFT) of the subjects were evaluated. Irisin levels were measured using ELISA.

Results

Circulating levels of irisin were significantly higher in acromegalic subjects compared to both controlled acromegalic subjects and controls. Moreover, irisin levels were elevated in controlled acromegalic subjects compared to controls. Irisin displayed a positive correlation with insulin resistance, cIMT, EFT, BMI, GH, and insulin-like growth factor (IGF-1) in acromegalic subjects. Irisin levels were independently associated with cIMT and EFT according to multiple regression analyses. There was an independent relationship between irisin and IGF-1.

Conclusions

Elevated irisin levels in acromegalic subjects were associated with cIMT and EFT, suggesting that irisin is a surrogate marker for cardiovascular risk in acromegalic subjects.

Keywords

Acromegaly Irisin Carotid intima media thickness Epicardial fat thickness Insulin resistance Insulin-like growth factor-1 

Abbreviations

ALT

alanine aminotransferase

AST

aspartate aminotransferase

ANOVA

one-way analysis of variance

BMI

body mass index

BUN

blood urea nitrogen

cIMT

carotid intima media thickness

CI

confidence interval

CV

coefficient of variability

DBP

diastolic blood pressure

FBG

fasting blood glucose

EFT

epicardial fat thickness

GH

growth hormone

HDL-C

high-density lipoprotein cholesterol

HOMA-IR

homeostasis model assessment of insulin resistance

IGF-1

insulin-like growth factor-1

LDL-C

low-density lipoprotein cholesterol

OGTT

oral glucose tolerance test

SBP

systolic blood pressure

T2DM

type 2 diabetes mellitus

VIF

variance inflation factor

Notes

Acknowledgements

We are grateful to Dr. Yeliz Pekçevik, who measured cIMT, to Dr. Ahmet Sayın, who measured EFT, and to Dr. Ayfer Çolak, who measured circulating apelin levels.

Author contributions

M.C. and M.D. participated in study design. M.C. and M.D. participated in study design, analyzed the data, wrote, reviewed and edited the manuscript. M.C. and M.D. provided serum samples and contributed to discussions of data interpretation. All authors reviewed and edited the manuscript. M.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Compliance with ethical standards

The subjects gave their oral and written informed consent before their inclusion in the study. The study adhered strictly to the principles of the Declaration of Helsinki as revised in 2008.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC et al (2012) A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463–468.  https://doi.org/10.1038/nature10777 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Crujeiras AB et al (2013) FNDC5/Irisin is not only a myokine but also an adipokine. PLoS One 8:e60563.  https://doi.org/10.1371/journal.pone.0060563 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Winn NC, Grunewald ZI, Liu Y, Heden TD, Nyhoff LM, Kanaley JA (2017) Plasma irisin modestly increases during moderate and high-intensity afternoon exercise in obese females. PLoS One 12:e0170690.  https://doi.org/10.1371/journal.pone.0170690 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lu Y, Li H, Shen S-W, Shen Z-H, Xu M, Yang C-J et al (2016) Swimming exercise increases serum irisin level and reduces body fat mass in high-fat-diet fed Wistar rats. Lipids Health Dis 15:93.  https://doi.org/10.1186/s12944-016-0263-y CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Huh JY, Mougios V, Kabasakalis A, Fatouros I, Siopi A, Douroudos II et al (2014) Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metab 99:E2154–E2161.  https://doi.org/10.1210/jc.2014-1437 CrossRefPubMedGoogle Scholar
  6. 6.
    Liu J-J, Wong MDS, Toy WC, Tan CSH, Liu S, Ng XW et al (n.d.) Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complicat 27:365–369.  https://doi.org/10.1016/j.jdiacomp.2013.03.002 CrossRefGoogle Scholar
  7. 7.
    Zhang C, Ding Z, Lv G, Li J, Zhou P, Zhang J (2016) Lower irisin level in patients with type 2 diabetes mellitus: a case-control study and meta-analysis. J Diabetes 8:56–62.  https://doi.org/10.1111/1753-0407.12256 CrossRefPubMedGoogle Scholar
  8. 8.
    Choi Y-K, Kim M-K, Bae KH, Seo H-A, Jeong J-Y, Lee W-K et al (2013) Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 100:96–101.  https://doi.org/10.1016/j.diabres.2013.01.007 CrossRefPubMedGoogle Scholar
  9. 9.
    Hee Park K, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE et al (2013) Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 98:4899–4907.  https://doi.org/10.1210/jc.2013-2373 CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Liu B-W, Yin F-Z, Qi X-M, Fan D-M, Zhang Y (2017) The levels of serum irisin as a predictor of insulin resistance in Han Chinese adults with metabolically healthy obesity. Clin Lab 63.  https://doi.org/10.7754/Clin.Lab.2016.160805
  11. 11.
    Pardo M, Crujeiras AB, Amil M, Aguera Z, Jiménez-Murcia S, Baños R et al (2014) Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol 2014:1–9.  https://doi.org/10.1155/2014/857270 CrossRefGoogle Scholar
  12. 12.
    Liu J-J, Liu S, Wong MDS, Tan CSH, Tavintharan S, Sum CF et al (n.d.) Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complicat 28:208–213.  https://doi.org/10.1016/j.jdiacomp.2013.09.011 CrossRefGoogle Scholar
  13. 13.
    Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF (2013) Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity--correlation with body mass index. Peptides 39:125–130.  https://doi.org/10.1016/j.peptides.2012.11.014 CrossRefPubMedGoogle Scholar
  14. 14.
    Aronis KN, Moreno M, Polyzos SA, Moreno-Navarrete JM, Ricart W, Delgado E et al (2015) Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events. Int J Obes 39:156–161.  https://doi.org/10.1038/ijo.2014.101 CrossRefGoogle Scholar
  15. 15.
    Sesti G, Andreozzi F, Fiorentino TV, Mannino GC, Sciacqua A, Marini MA et al (2014) High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol 51:705–713.  https://doi.org/10.1007/s00592-014-0576-0 CrossRefPubMedGoogle Scholar
  16. 16.
    Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83:3476–3479.  https://doi.org/10.1210/jcem.83.10.5161 CrossRefPubMedGoogle Scholar
  17. 17.
    Silha JV, Krsek M, Hana V, Marek J, Jezkova J, Weiss V et al (2003) Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin Endocrinol 58:736–742.  https://doi.org/10.1046/j.1365-2265.2003.01789.x CrossRefGoogle Scholar
  18. 18.
    Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN et al (2008) Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 93:2334–2343.  https://doi.org/10.1210/jc.2007-2780 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Woodhouse LJ, Mukherjee A, Shalet SM, Ezzat S (2006) The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev 27:287–317.  https://doi.org/10.1210/er.2004-0022 CrossRefPubMedGoogle Scholar
  20. 20.
    Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148.  https://doi.org/10.1210/jc.2009-2670 CrossRefPubMedGoogle Scholar
  21. 21.
    Katznelson L, Atkinson JLD, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK et al (n.d.) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Endocr Pract 17(Suppl 4):1–44Google Scholar
  22. 22.
    Touboul P-J, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N et al (2012) Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, B. Cerebrovasc Dis 34:290–296.  https://doi.org/10.1159/000343145 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 2009;22:1311–1319; quiz 1417–8. doi: https://doi.org/10.1016/j.echo.2009.10.013 CrossRefGoogle Scholar
  24. 24.
    Qiu S, Cai X, Yin H, Zügel M, Sun Z, Steinacker JM et al (2016) Association between circulating irisin and insulin resistance in non-diabetic adults: a meta-analysis. Metabolism 65:825–834.  https://doi.org/10.1016/j.metabol.2016.02.006 CrossRefPubMedGoogle Scholar
  25. 25.
    Fukushima Y, Kurose S, Shinno H, Cao Thi Thu H, Tamanoi A, Tsutsumi H et al (2016) Relationships between serum irisin levels and metabolic parameters in Japanese patients with obesity. Obes Sci Pract 2:203–209.  https://doi.org/10.1002/osp4.43 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Jameel F, Thota RN, Wood LG, Plunkett B, Garg ML (2015) Sex-dependent association between circulating irisin levels and insulin resistance in healthy adults. J Nutr Intermed Metab 2:86–92.  https://doi.org/10.1016/j.jnim.2015.10.001 CrossRefGoogle Scholar
  27. 27.
    Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH et al (1998) The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128:262–269CrossRefGoogle Scholar
  28. 28.
    Meenakshi K, Rajendran M, Srikumar S, Chidambaram S (2016) Epicardial fat thickness: a surrogate marker of coronary artery disease – assessment by echocardiography. Indian Heart J 68:336–341.  https://doi.org/10.1016/j.ihj.2015.08.005 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Topaloglu O, Sayki Arslan M, Turak O, Ginis Z, Sahin M, Cebeci M et al (2014) Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules. Clin Endocrinol 80:726–734.  https://doi.org/10.1111/cen.12356 CrossRefGoogle Scholar
  30. 30.
    Ozkan C, Altinova AE, Cerit ET, Yayla C, Sahinarslan A, Sahin D et al (2015) Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary 18:621–629.  https://doi.org/10.1007/s11102-014-0621-6 CrossRefPubMedGoogle Scholar
  31. 31.
    Stratigou T, Dalamaga M, Antonakos G, Marinou I, Vogiatzakis E, Christodoulatos GS et al (2018) Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors. Endocrine 61:83–93.  https://doi.org/10.1007/s12020-018-1550-3 CrossRefPubMedGoogle Scholar
  32. 32.
    Polyzos SA, Mathew H, Mantzoros CS (2015) Irisin: a true, circulating hormone. Metabolism 64:1611–1618.  https://doi.org/10.1016/j.metabol.2015.09.001 CrossRefPubMedGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2019

Authors and Affiliations

  1. 1.Division of Endocrinology and Metabolism, Department of Internal MedicineIzmir Bozyaka Training and Research HospitalIzmirTurkey
  2. 2.Division of Endocrinology and Metabolism, Department of Internal MedicineIzmir Tepecik Training and Research HospitalIzmirTurkey

Personalised recommendations